NCT06557239

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy for Anxiety and Depression: a Pilot Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10 (actual)
• Sponsor: Tatiana Aboulafia Brakha · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance). There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine

Conditions

• Depression, Anxiety

Interventions

Type	Name	Description
DRUG	Lysergic Acid Diethylamide (LSD)	one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department

Timeline

• Start date: 2024-08-05
• Primary completion: 2024-12-11
• Completion: 2024-12-11
• First posted: 2024-08-16
• Last updated: 2025-05-16

Locations

1 site across 1 country: Switzerland